Journa Unveils Bondia™: A Daily Synbiotic Medical Food for the Dietary Management of Bone Loss Associated with Menopause, Weight, and Aging

Developed by Solarea Bio, an emerging biotechnology company, Bondia™ leverages the proprietary Microscape™ Technology, which identifies and optimizes beneficial microbes naturally present in fruits and vegetables to create clinically effective medical foods. This breakthrough harnesses the potential of the natural microbiome to deliver clinically validated health benefits.

Bondia™ has undergone rigorous scientific evaluation, including a double-blind, placebo-controlled clinical trial involving 286 women. The study demonstrated Bondia™’s ability to slow bone loss in a prespecified population. The results are pending peer review and publication. Designed for daily consumption, Bondia™ offers a convenient, natural and clinically effective option for individuals seeking to manage bone health concerns.

"The rigorous scientific evaluation of Bondia™, including a double-blind, placebo-controlled clinical trial involving 286 women, demonstrates its effectiveness in slowing bone loss in a prespecified population," said Ilissa Larimore, Chief Commercial Officer. "This offers a compelling option for those seeking to proactively manage their bone health."

To personally explore the product and embark on a journey towards supporting bone health, individuals are encouraged to visit www.journahealth.com. Physicians eager to extend the benefits of Bondia™ to their patients can obtain more information by contacting support@journahealth.com. For investment inquiries, please contact eschott@solareabio.com.

About Journa:

Journa is a consumer health brand pioneered by Solarea Bio, a Boston-based commercial-stage biotechnology company.

Contact: media@solareabio.com